EchoIQ Limited (AU:EIQ) has released an update.
Echo IQ Limited has announced the submission of their AI-based EchoSolv-AS tool for FDA approval, which could significantly enhance the detection of aortic stenosis in the US if cleared. The company anticipates a decision within 90 days, potentially leading to increased commercial uptake and integration into clinical workflows. They have also engaged consultants to secure US insurance reimbursement codes, aiming to boost the tool’s adoption in hospital settings.
For further insights into AU:EIQ stock, check out TipRanks’ Stock Analysis page.
